Financial Performance - The company's revenue reached RMB 131867 million, a 25% year-over-year increase[11] - Gross profit increased to RMB 21510 million, representing a 28% increase[11] - Net profit attributable to shareholders was RMB 2077 million, a decrease of 203%[11] - Operating cash flow significantly improved, reaching RMB 1531 million, a 2501% increase compared to the previous year[11] Business Segments - Pharmaceutical manufacturing business revenue was RMB 2481 billion, up 43% year-over-year, while segment gross profit margin decreased by 08 percentage points to 593%[19, 20] - Commercial business revenue increased by 23% to RMB 108330 million[62] - The medical device business achieved revenue of RMB 18 billion, an 8% year-over-year increase[70] Strategic Initiatives - The company completed the acquisitions of Nigale and Tasly to expand into the medical device sector and solidify its position in the TCM industry[22, 24] - The company is committed to innovative R&D, with 476 total projects under research and development, including 178 new drugs[36] - The company is strengthening international expansion, with overseas API revenue reaching RMB 360 million in the first half of the year[53, 58]